Photoreceptor-Based Biomarkers in AOSLO Retinal Imaging

Katie M. Litts,1 Robert F. Cooper,2,3 Jacque L. Duncan,4 and Joseph Carroll1,5

1Department of Ophthalmology & Visual Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4Department of Ophthalmology, University of California, San Francisco, California, United States
5Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Correspondence: Joseph Carroll, Department of Ophthalmology & Visual Sciences, Medical College of Wisconsin, 925 N 87th Street, Milwaukee, WI 53226-0509, USA; jcarroll@mcw.edu.
Submitted: March 14, 2017
Accepted: July 28, 2017
Citation: Litts KM, Cooper RF, Duncan JL, Carroll J. Photoreceptor-based biomarkers in AOSLO retinal imaging. Invest Ophthalmol Vis Sci. 2017;58:BIO255–BIO267. DOI: 10.1167/iovs.17-21868

Improved understanding of the mechanisms underlying inherited retinal degenerations has created the possibility of developing much needed treatments for these relentless, blinding diseases. However, standard clinical indicators of retinal health (such as visual acuity and visual field sensitivity) are insensitive measures of photoreceptor survival. In many retinal degenerations, significant photoreceptor loss must occur before measurable differences in visual function are observed. Thus, there is a recognized need for more sensitive outcome measures to assess therapeutic efficacy as numerous clinical trials are getting underway. Adaptive optics (AO) retinal imaging techniques correct for the monochromatic aberrations of the eye and can be used to provide nearly diffraction-limited images of the retina. Many groups routinely are using AO imaging tools to obtain in vivo images of the rod and cone photoreceptor mosaic, and it now is possible to monitor photoreceptor structure over time with single cell resolution. Highlighting recent work using AO scanning light ophthalmoscopy (AOSLO) across a range of patient populations, we review the development of photoreceptor-based metrics (e.g., density/geometry, reflectivity, and size) as candidate biomarkers. Going forward, there is a need for further development of automated tools and normative databases, with the latter facilitating the comparison of data sets across research groups and devices. Ongoing and future clinical trials for inherited retinal diseases will benefit from the improved resolution and sensitivity that multimodal AO retinal imaging affords to evaluate safety and efficacy of emerging therapies.

Keywords: adaptive optics, retinal degeneration, retinal imaging, photoreceptor, biomarkers

The rapid development of therapeutic interventions for ophthalmic diseases is providing potential treatments for inherited retinal degenerations. Important for the success of emerging clinical trials will be the ability to evaluate the safety and efficacy of the prospective treatment(s) with high sensitivity. Measures of visual function are accepted commonly as primary endpoints for clinical trials by regulatory agencies because they describe the impact of disease and treatment on the patient’s perception of the world.1 However, as photoreceptor loss occurs slowly in many retinal degenerations, it can take many years to measure changes in visual function reliably using clinically available technologies.2–4 In clinical trials, waiting years for a measurable change may not be feasible due to time and economic constraints. This necessitates the need for more sensitive, reliable outcome measures to assess treatment safety and efficacy.

It is possible to monitor diseases affecting the retina and the effect of potential therapeutic interventions through direct visualization of individual photoreceptors with tools for high-resolution in vivo imaging of the retina. Adaptive optics (AO), in combination with various other retinal imaging modalities, has revolutionized the way in which we visualize the living human retina.5,6 AO corrects the monochromatic aberrations of the eye,7 and when combined with techniques like fundus imaging, scanning laser ophthalmoscopy (SLO), and optical coherence tomography (OCT), the result is nearly diffraction-limited imaging of the living retina.6,8,9 Compared to currently available clinical tools, this improved resolution makes AO retinal imaging a sensitive method for monitoring retinal degeneration. For example, recent studies using AO retinal imaging in eyes with retinal diseases have demonstrated that significant decreases in cone photoreceptor spatial density and increases in cone spacing are observable before visual acuity becomes abnormal.10–13 In addition, multiple examples demonstrate a lack of correlation between photoreceptor structure seen with AOSLO and clinical OCT.14–17 Confocal and nonconfocal split-detector AOSLO each have their own advantages and limitations. Despite the exquisite resolution provided by AO-based retinal imaging tools, photoreceptor-based metrics have not been validated as outcome measures for multicenter clinical trials, partly due to the lack of standardized AO-equipped retinal imaging systems and analytical software. Nevertheless, many groups have used AO imaging tools to provide important insight into how retinal degenerations affect photoreceptor survival during disease progression and in response to therapies.11–13,15–18–21

The ultimate use of any ophthalmic imaging modality generally is limited by the ability to extract quantitative information from the images. In this manuscript, we review photoreceptor-based biomarkers (e.g., density/geometry, re-
effectivity, and size) that are being used or have been proposed for analyzing any AO retinal images of the photoreceptor mosaic, with a focus on AOSLO. Through validation and the assessment of reliability and repeatability, these biomarkers may become valuable outcome measures in current and future clinical trials targeting patients with inherited retinal degenerations. In addition, such biomarkers could be useful to assess disease progression and treatment response in animal models of retinal disease, as it is now possible to resolve the cone mosaic in a number of animal models using a variety of imaging tools. Beyond measuring treatment response, it is possible that AO retinal imaging could be used to select specific patients for a given treatment, as accurate assessment of remnant cone structure in diseases for which cone-directed gene therapy is being considered would be a requisite step to establish the visual and therapeutic potential of a given retina. An example of this is shown in Figure 1, where two patients with achromatopsia have dramatically different numbers of remnant cones; thus, one might not expect the same therapeutic response in these individuals. Finally, although this review will focus on AOSLO-based photoreceptor biomarkers, it should be noted that AO retinal imaging has many applications in humans, including visualizing RPE, blood vessels, and ganglion cells (Liu Z, et al. IOVS 2017;58:ARVO E-Abstract 3430), that are explored in depth in other reviews.

**Origins of Photoreceptor Signals by AO Retinal Imaging**

Before exploring potential biomarkers, it is worth briefly examining the way in which photoreceptors are visualized in AO retinal images. Although there is controversy on the cellular origin of OCT photoreceptor signals from AO-equipped and non-AO OCT, there appears to be more consensus about the origin of the signals when using other AO-equipped technology. AO retinal imaging allows for noninvasive imaging of individual cone photoreceptors through increased lateral resolution and photoreceptor waveguiding via the optical Stiles-Crawford effect. The visualization of photoreceptors is enabled in part by the high refractive index of the photoreceptor relative to the surrounding interphotoreceptor matrix. The backscattered light at the interface between the outer segments and RPE is coupled back through the cone and provides the directional component of the reflected light. Thus, it is thought that for a photoreceptor to be visible by waveguiding, its outer segment must be intact and contacting the RPE apical processes. In OCT, this is seen as an intact interdigization zone (IZ) or cone outer segment tip (COST) band, depending on the technology and imaging system used. The number of modes a photoreceptor can support depends on the wavelength of light and the diameter of the photoreceptor itself. Thus, while foveal cones only exhibit a single mode (having a Gaussian-like reflectance profile), the larger perifoveal cones may have multiple modes. There continues to be extensive work into trying to understand how light interacts with photoreceptors and the source of photoreceptor signals in AO retinal imaging.

Conventionally, AOSLO imaging uses a confocal pinhole to detect waveguided light from photoreceptors. AOSLO systems can resolve the smallest cones in the fovea as well as rods in the perifovea and periphery (Fig. 2). Despite excellent resolution, a number of factors interfere with reliable cone visualization. Cones with low reflectivity and with multiple modes or abnormal reflectivity that can occur in some diseases may be missed, counted multiple times, or misidentified as rods. Reflectivity from the RPE also can confound the photoreceptor signal, making the cone mosaic difficult to interpret, especially in eyes with photoreceptor degeneration. To guide the analysis of confocal AO retinal imaging, nonconfocal methods can be used. Nonconfocal methods include split-detector AOSLO and the use of one or more offset apertures to collect scattered light from photoreceptors. With split-detector AOSLO, the multiple-scattered light is captured by two separate detectors, and signals from...
and split-detector AOSLO images can be acquired simultaneously, they should be viewed as complementary imaging modalities for assessing cone structure, each with their own advantages and limitations.

Next, we will explore the use of three general classes of photoreceptor-based biomarkers including photoreceptor density/geometry, reflectivity, and size.

**Photoreceptor Density and Geometry**

The retinal image itself can be used to extract information about the photoreceptor mosaic. For example, the local orientation of the cone mosaic can be extracted directly from the cone image. Cones in the photoreceptor mosaic are arranged in a regular, but imperfect, triangular lattice. Each cone forms a polygon "submosaic" with its neighbors, where the locations of a given cone's neighbors form the vertices of the polygon. To quantify the anisotropy of the mosaic, one can extract the "orientation" of each submosaic, defined by the rotation of this polygon. This can be done on the scale of an individual submosaic, or as an average of submosaics. In addition, the modal spacing of the cones (also referred to as intercell distance (ICD)) can be extracted directly from the Fourier transform of the image, which for normal retinas will have an annular appearance - this annulus often is called "Yellott's ring". There are limitations to this method in that the power spectrum contains information about the object profile itself in addition to the spacing of the objects in the image; this is less of an issue in a contiguously packed mosaic of cells of uniform size, but becomes disabling when working with images of the peripheral photoreceptor mosaic. In addition, the contrast of Yellott's ring often decreases in areas of retinal degeneration or cone loss, making it difficult to extract an accurate estimate of modal spacing. Finally, extracting either average anisotropy or modal spacing relies on the assumption that the mosaic is packed in a regular triangular lattice, which often does not hold in eyes with retinal degeneration.

As a result of inherent limitations of these image-based metrics, an important first step in extracting quantitative information about the photoreceptor mosaic often involves the derivation of coordinate locations for the individual cells of interest. Although cones can be identified manually, there are a growing number of effective semiautomated and automated tools. Once the cells of interest have been identified in the image, any number of metrics can be calculated automatically. While cell density and ICD are the most commonly used metrics to describe the cone mosaic, there has been a recent expansion to consider other types of metrics, such as percentage of hexagonal Voronoi cells, nearest neighbor distance (NND), farthest neighbor distance (FND), nearest neighbor regularity (NNR), linear dispersion index (LDi), number of neighbors regularity (NoNR), Voronoi cell area regularity (VCAR), heterogeneity packing index (HPi), and cell orientation or directionality (Fig. 4). Together, these metrics have been applied to a wide range of retinal diseases. However, it is important to keep in mind that for these metrics, errors in the process of identifying the cones in an image often constrain the repeatability and reliability of a given metric. Thus, it is critical that one understands the capabilities of the particular cone detection algorithm used for their images.

Different metrics have been shown to have markedly different sensitivities for detecting cone loss. While it may seem counterintuitive, the most sensitive metric cannot be assumed to be the best metric across all applications. In other words, for a particular study, the most appropriate metric for analysis should be sensitive enough to detect anticipated...
Figure 3. Resolving cone inner and outer segment structure with AOSLO. Shown are confocal (A) and split-detection (B) images from the parafoveal retina of a patient with \textit{CNGA3}-associated ACHM. The color-merged image (C) has the confocal image displayed in \textit{green} and the split-detection image in \textit{red}. Scale bar: 50 \(\mu\text{m}\). (D) Photoreceptor schematic based off of a model presented by Jonnal et al.\textsuperscript{149} – the signal (I) requires intact photoreceptors\textsuperscript{142,149} and can vary as a result of small perturbations in photoreceptor structure. Multiply-scattered light from the RPE and inner segments is rejected by confocal AOSLO.

Figure 4. A schematic of a hexagonally arranged patch of cones illustrating the relationship between the distance measurements used by Cooper et al.\textsuperscript{87} A single cone (\textit{red circle}) and its six closest neighbors (\textit{open circles}) are highlighted for clarity. The NND is defined as the distance from a given cone to its closest neighbor (\textit{orange dashed line}), and ICD is defined as the average distance between a cone and all of its neighbors (\textit{dashed lines}). To mitigate boundary effects, only cones with bound Voronoi regions (\textit{shaded region}) are included when calculating each metric. The regularity of each of these metrics (M) is defined as the mean ($\mu_M$) of the metric for all cones with bounded Voronoi cells, divided by the metric’s SD ($\sigma_M$). Reprinted from Cooper RF, Wilk MA, Tarima S, Carroll J. Evaluating descriptive metrics of the human cone mosaic. \textit{Invest Ophthalmol Vis Sci.} 2016;57:2992–3001. Licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
abnormalities, but robust enough not to be skewed by errors in cell identification. For example, it recently was shown that NND and density recovery profile distance (DRPD), a method to measure ICD, are relatively insensitive to undersampling; even after half of the cones were removed, the mosaic still was detected as normal (Fig. 5).87 Thus, spacing metrics like these, which are insensitive to small changes in the mosaic, would provide a conservative measure of photoreceptor survival and be insensitive to early cone loss when monitoring a mosaic over time.62,87 Conversely, regularity metrics generally are more sensitive. For example, it was shown that NoNR reliably classifies a mosaic as significantly different from normal when only 10% of cones were removed.87 At the same time, NoNR and other regularity metrics would be more susceptible to errors in the initial identification of cone coordinates. Disambiguation of real cone degeneration from differences in cone identification is especially important in patients with retinal disease, as visibility of the cone mosaic can be altered or obstructed by inner retinal cysts and microcysts present in conditions, such as cystoid macular edema, RP, macular telangiectasia, and age-related macular degeneration.82,101–104 Moreover, combining metrics with varying sensitivities may provide a more complete picture of the cone mosaic.87,88,105

For example, a recent study demonstrated that complementary use of two regularity metrics (LDi and HPi) provided 100% accuracy to discriminate controls from patients with diabetes and no clinical signs of diabetic retinopathy.88 Finally, it is important to note that most metrics have been applied nearly exclusively to the cone mosaic. As many AO imaging systems also can resolve rod photoreceptors,9,106–108 it will be important to reexamine these metrics for the rod mosaic. As the cells within the rod and cone submosaics differ in size and density, it will be important to examine how metrics describing these interleaved mosaics interact with one another in the normal and diseased retina. However, it seems certain that the behavior of various metrics will vary as a function of retinal eccentricity, as a result of the changing rod-to-cone ratio. Establishing the reliability and repeatability of each metric is essential to the correct interpretation of data from clinical trials (and to eventual acceptance of a metric by the Food and Drug Administration [FDA]). Importantly, this should be done at multiple centers; thus, inclusion of AO retinal imaging in natural history studies of disease progression offers opportu-
Photoreceptor-Based AOSLO Biomarkers

One of the most salient features of the photoreceptor mosaic is the cell-to-cell and temporal variability in reflectivity, which is even seen in non-AO images of the cone mosaic. Cone reflectivity changes have been observed qualitatively and quantitatively in normal and diseased eyes using confocal AOSLO and flood-illuminated AO. Normal waveguiding cones appear as bright spots, whereas non-waveguiding cones appear dark, suggesting an altered outer segment. Interestingly, a lack of sensitivity or cone function has been observed over areas with reduced or no reflectivity, for example, in color vision deficiencies, achromatopsia, Stargardt disease, RP, and age-related macular degeneration. Yet residual sensitivity has been observed in areas with reduced or no reflectivity in macular telangiectasia, age-related macular degeneration, and normal eyes. The relationship between reflectivity in confocal AO retinal imaging and cone function remains to be defined more clearly.

In normal eyes, cones exhibiting low reflectance compared to neighboring cones do not necessarily correlate with decreased sensitivity. Cone reflectivity can vary depending on the direction of illumination, and has been observed to change over time (seconds and minutes to hours) and from cone to cone. Long-term variation in cone reflectivity has been suggested to result from outer segment renewal, and short-term reflectivity changes have been attributed to phototransduction. Similar to cones, the reflectivity of individual rod photoreceptors has been observed to vary over time in health and disease. Additionally, cone reflectivity changes after bleaching of the photopigment, which has been used to identify the spectral identity of individual cones. Cone and rod reflectivity could be used as metrics, for example, to distinguish GNAT2-associated achromatopsia with higher cone reflectivity versus CNGA3- or CNGB3-associated achromatopsia with lower cone reflectivity.

In addition to intrinsic variability in reflectivity, photoreceptors also change their reflectance in response to a stimulus. This property persists over a wide range of modalities, imaging wavelengths, and retinal eccentricities. These stimulus-evoked changes could be used as a metric of photoreceptor health, and efforts to characterize their response properties are ongoing. In particular, it will be important to examine the reflectance response as a function of stimulus properties (e.g., irradiance, duration, wavelength). It has been postulated that changes in a cone’s outer segment optical path length are causing the changes in reflectance. Validated approaches could provide a highly sensitive, noninvasive alternative to electrophysiology to directly monitor photoreceptor structure and/or function.

An inherent challenge in measuring photoreceptor reflectivity is identifying the photoreceptors to be measured. As mentioned above, this often is done using the very reflectivity signal of interest, this intrinsic variability of cones over time as well as the presence of multiple waveguide modes and noncone reflectivity sources (i.e., RPE) severely confound this process. One solution to overcome reduced or ambiguous cone reflectivity is to leverage the reliable cone identification from a corresponding nonconfocal image, and use those coordinates to overlay on a confocal image to identify photoreceptors for subsequent reflectivity measurements. This approach could be attractive especially in areas of cone degeneration, where it can be challenging to identify cones reliably based on their reflectivity alone (e.g., within the transition zone in patients with RP or choroideremia), and further highlights the complementary nature of split-detector and confocal AOSLO.
Photoreceptor Size

The process of cone degeneration is fairly well understood in inherited retinal degenerations; histology studies have shown the first structural changes are shortening of the cone outer segments, followed by swelling and degeneration of the inner segment, and finally loss of the cell body.\(^5\)\(^6\)\(^7\) Thus, a final photoreceptor-based biomarker to consider is photoreceptor size (e.g., outer segment length and cone diameter). Using OCT, outer segment length has been shown to be abnormal in some diseases, such as albinism\(^1\)\(^2\)\(^3\)\(^4\) and Best disease.\(^1\)\(^5\)\(^4\) Care should be used, as measurement of outer segment length can be affected by light adaptation and segmentation errors of the retinal layers.\(^1\)\(^6\) AO-OCT affords more sensitive measurement of outer segment length than commercial OCT systems, having been used to monitor outer segment renewal on the level of a single cell.\(^1\)\(^7\)\(^8\) In our experience, it is difficult to resolve individual cones in the fovea or rods in the normal retina. However, in many pathologic cases in which some cones have been lost, the remaining photoreceptor inner segments enlarge.\(^5\)\(^6\)\(^7\)\(^8\)\(^9\)\(^10\) This often results in easier visualization of foveal cones using split-detector AOSLO imaging (Fig. 6). The enlargement of remnant cones also has been quantified using split-detector AOSLO in patients with choroideremia\(^2\)\(^0\) and RP (Fig. 6).\(^1\)\(^2\) As the ability to assess photoreceptor size is relatively new, it will be interesting to see how it is applied in other retinal degenerations.

CHALLENGES AND LOOKING FORWARD

The future of clinical trials using AO retinal imaging tools to monitor photoreceptors is promising. To improve the clinical use of AO retinal imaging, the challenges going forward include creating and disseminating automated tools, creating multicenter normative databases, standardizing datasets for comparison, and validating any and all biomarkers, including those that may be developed in the future. In addition, hardware-related issues limit the clinical application of AO retinal imaging. For example, at the time of writing this review, there is no 510k-cleared device, though the rtx1 system from Imagine Eyes (Orsay, France) has received approval in the European Union, Japan, and Australia. While custom laboratory devices are available from Physical Sciences, Inc. (Andover, MA, USA)\(^1\)\(^7\)\(^8\) and Boston Micromachines (Boston, MA, USA),\(^1\)\(^9\) the lack of clinical equipment for clinical use in the United States certainly has slowed adoption. Beyond access, there are hardware standardization issues, as the devices available include flood-illuminated AO, AOSLO, and AO-OCT. There has been little work exploring how the different embodiments of
AO retinal imaging relate to each other in the normal and diseased retina, and this limits the ability to conduct multisite studies. Regardless of the modality, the systems should be capable of resolving foveal cones and perifoveal rods to facilitate photoreceptor studies.

Need for Automated Tools

Regardless of the class of biomarker (density/geometry, reflectivity, and size) used, there is a need for automated analytical tools to increase the clinical use of AO retinal imaging. The repeatability and reliability of a photoreceptor-based metric is limited by the ability to detect and identify cones, which often is a required step in quantitative analysis of the photoreceptor mosaic. Manual identification of cones is time-consuming and can result in low repeatability if observers are not experienced in images of retinal disease. 114 For cone identification, many groups have developed methods to detect cones automatically in confocal AO imaging. 55,69–71,159,162,163 Garrioch et al. 71 showed that manual correction of missed cones from an automated algorithm significantly increased repeatability, though newer automated algorithms have shown comparable repeatability. 164 Automatic cone identification becomes less reliable when rods begin scattering the mosaic or RPE cells become visible in eyes with retinal degeneration. Therefore, automatic photoreceptor algorithms are needed to identify cones and rods within the same image. 68,158 and to disambiguate multimodal cones from rods in the perifovea. With the distinctive appearance of cones in split-detector AO imaging, existing algorithms for confocal AO or flood-illuminated AO do not work. An algorithm was developed by Cunefare et al. 67 to identify individual cones in split-detector AO images based on their characteristic pairs of horizontally separated dark and bright regions. The algorithm underestimates high cone density found in healthy eyes, with smaller cones in the fovea, but preliminary performance on irregular mosaic shows promise in characterizing pathology. 67,75 Other algorithms have been published, 164,166 and these efforts represent an important first step in developing robust cone counting software for split-detector images. It again is important to characterize the performance of the specific cone detection algorithm used, 77 as it may affect the subsequent choice of metric for analyzing the mosaic. 57

Multicenter Normative Databases

For future clinical trials, multicenter normative databases are needed for comparing data sets. Additionally, the AOSLO community lacks photoreceptor mosaic datasets available in the public domain, which would aid in standardization of analyses. Currently, groups have established their own normative data set with their own systems, 107,108,166–168 and few multicenter trials are conducted using identical acquisition systems at all sites. When comparing normative data to eyes with retinal disease, it should be noted that the preferred retinal locus of fixation and peak cone density are not always colocalized in normal 160,170 or in diseased eyes. 103 A static reference point for sampling should be considered if the primary interest of a study is the anatomical fovea, fixation, and/or peak cone density, which may not be located in the same position. In some diseases, one or more foveal landmarks are affected by retinal degeneration and cannot be used; the location of the fovea may be estimated relative to the optic nerve head. 171 Normative databases should include photoreceptor mosaics across various eccentricities aligned to other imaging modalities, along with technical details of each AOSLO system including image scale, field of view, imaging wavelength, and axial length of the subject. This would aid toward cross-site comparisons of analysis algorithms and testing of photoreceptor biomarkers. With comparing data sets comes the challenge of longitudinal alignment of AO retinal images collected over extended time periods, which is an open problem particularly in the actively degenerating retina.

Structure/Function Relationships

For the biomarkers described above to be accepted by the FDA, it will be important to define how they correlate with measures of visual function. However, it is worth keeping in mind that a lack of correlation does not necessarily mean the AO biomarker is not valid, rather in many cases it simply is more sensitive. For example, patients with achromatopsia have no cone function, yet split-detector AO imaging has revealed that remnant cones are present (Fig. 1). 17 One would argue that the structural information only is useful provided it can be extracted with high reliability and repeatability. In addition, cone density is correlated significantly with best-corrected visual acuity and foveal sensitivity, but can decrease by more than a third to a half below normal before visual function becomes abnormal. 11,12 These data suggest that changes in cone spacing/density may be more sensitive biomarkers for assessing therapeutic response. Indeed, Talcott et al. 15 used confocal AO to monitor cone structure after experimental treatment with cilary neurotrophic factors in patients with RP and demonstrated differences in cone structure between treated and untreated eyes, in the absence of any changes in visual function (e.g., visual acuity, visual field sensitivity, or electroretinographic responses). Future studies should continue to examine how photoreceptor structure using metrics described in this review correlates with visual function in a broader range of retinal degenerations.

How can one still have visual function despite the lack of visible cones (e.g., reduced cone density or increased ICD)? There are multiple mechanisms for the visual system to protect vision. The imperfect optics of the eye distort the stimulus; this, along with overlapping receptive fields in the visual system, creates a spatial redundancy in the stimulus. 135 In addition, eyes are moving constantly, including fixational eye movements, to increase visual acuity. 172 Recent studies of eyes with vision loss, including macular telangiectasia, 102 acute idiopathic blind spot enlargement syndrome, 173 and bilateral foveolitis, 140 have demonstrated cones that are not visible using confocal AO imaging, in regions on OCT images with reduced reflectivity or disruption of the ellipsoid zone, but in which the external limiting membrane is visible. If the interface between the outer segments and RPE cells is disrupted, visual function and reflectivity may be reduced, but if the external limiting membrane is visible, cone inner segments (and perhaps abnormally waveguiding outer segments) are present. These “dysflective” cones with abnormal reflective properties on confocal images have reduced, but measurable, visual function, 140 and provide insight into the relationship between the origin of waveguiding cone photoreceptors using confocal AO, OCT, and visual function. These studies highlight the importance of using structural and functional measurements that operate on similar spatial scales—AO microperimetry is an exciting new application that will allow more precise assessment of the relationship between cone structure and function in the living retina. 102,150,140,174–176

Comparing AO Images to Conventional Clinical Images

In addition to probing the relationship between AO biomarkers and retinal function, examining relationships with routine clinical imaging will be critical to defining the future role of AO imaging.
retinal imaging in the clinic. In addition, such comparisons facilitate the interpretation of images across different modalities. For example, a correlation has been observed between hyperautofluorescent changes on fundus autofluorescence imaging and disruption of the IZ on OCT and loss of reflective cone profiles on flood-illuminated AO retinal imaging in RP.\textsuperscript{47} Additionally, attenuation of the IZ colocalized with absent cone reflectance on flood-illuminated AO retinal images, and recovery of the IZ accompanied restoration of normal cone reflectance on AO retinal images.\textsuperscript{48} In patients with albinism, peak cone density measured with confocal AOSLO has been shown to correlate with foveal outer segment length measured with OCT.\textsuperscript{152} Split-detection AOSLO has been shown to identify cones in areas of low or ambiguous ellipsoid zone reflectivity on OCT and confocal AOSLO in a variety of retinal disorders.\textsuperscript{37} These studies highlight AO retinal imaging tools as complementary to, rather than a replacement for, conventional clinical imaging modalities.

**CONCLUSIONS**

A multimodal imaging and functional testing approach is necessary for moving forward with clinical trials. AO retinal imaging should have an important role in these efforts, serving as an objective and sensitive method to detect anatomical changes. As the sensitivity of photoreceptor-based metrics exceeds that of conventional tests of visual function, they may be useful in detecting “subclinical” changes over time or in response to treatment. It is important to be mindful of the expected changes to select the photoreceptor-based metric with the appropriate sensitivity. Despite these challenges, we are just at the beginning of the opportunities that AO retinal imaging affords us in understanding retinal diseases on the microscopic scale in vivo, and the ability to monitor photoreceptor density/geometry, reflectivity, and size as outcome measures in clinical trials. The future is bright for using sensitive metrics to monitor photoreceptors well before vision changes in inherited retinal diseases.

**Acknowledgments**

The authors thank Margaret Strampe and Brian Higgins for their assistance.

Supported by the National Center for Advancing Translational Sciences and the National Eye Institute of the National Institutes of Health (NIH; Bethesda, MD, USA) under award numbers UL1TR001436, R01EY024969, R01EY017607, P30EY001931, and UL1TR0001436, R01EY024969, R01EY017607, P30EY001931, and P30EY0001436, and by Foundation Fighting Blindness and Research to Prevent Blindness (Nelson Trust Award for Retinitis Pigmentosa to JLD and an Unrestricted Grant to UCSF). The authors alone are responsible for the content and writing of this paper.

Disclosure: **K.M. Litts**, None; **R.F. Cooper**, None; **J.L. Duncan**, Neurotech USA, Inc. (F), AGTC (C), Spark Therapeutics (C), JCyte (C), Novelion (C), Ionis (C), SparingVision (C); **J. Carroll**, AGTC (F), MeiraGTx (C), OptoVue (F)

**References**


